AU2002341145A1 - Pharmaceutical formulation comprising more than 15% tamoxifen - Google Patents

Pharmaceutical formulation comprising more than 15% tamoxifen

Info

Publication number
AU2002341145A1
AU2002341145A1 AU2002341145A AU2002341145A AU2002341145A1 AU 2002341145 A1 AU2002341145 A1 AU 2002341145A1 AU 2002341145 A AU2002341145 A AU 2002341145A AU 2002341145 A AU2002341145 A AU 2002341145A AU 2002341145 A1 AU2002341145 A1 AU 2002341145A1
Authority
AU
Australia
Prior art keywords
tamoxifen
pharmaceutical formulation
formulation
pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002341145A
Other languages
English (en)
Inventor
Marcel De Matas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of AU2002341145A1 publication Critical patent/AU2002341145A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2002341145A 2001-10-24 2002-10-23 Pharmaceutical formulation comprising more than 15% tamoxifen Abandoned AU2002341145A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0125492.9 2001-10-24
GBGB0125492.9A GB0125492D0 (en) 2001-10-24 2001-10-24 Formulation
PCT/GB2002/004835 WO2003035043A2 (en) 2001-10-24 2002-10-23 Pharmaceutical formulation comprising more than 15% tamoxifen

Publications (1)

Publication Number Publication Date
AU2002341145A1 true AU2002341145A1 (en) 2003-05-06

Family

ID=9924411

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002341145A Abandoned AU2002341145A1 (en) 2001-10-24 2002-10-23 Pharmaceutical formulation comprising more than 15% tamoxifen

Country Status (6)

Country Link
US (1) US20050042279A1 (enExample)
EP (1) EP1448171A2 (enExample)
JP (1) JP2005508971A (enExample)
AU (1) AU2002341145A1 (enExample)
GB (1) GB0125492D0 (enExample)
WO (1) WO2003035043A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI547431B (zh) * 2004-06-09 2016-09-01 史密斯克萊美占公司 生產藥物之裝置及方法
CZ297446B6 (cs) * 2004-09-30 2006-12-13 Pliva - Lachema A. S. Zpusob prípravy orální pevné lékové formy a orální pevná léková forma pripravená tímto zpusobem
US10201549B2 (en) * 2013-06-14 2019-02-12 Professional Compounding Centers Of America (Pcca) Testosterone combined with anastrozole injection solutions
CN103393603B (zh) * 2013-07-22 2015-04-01 南通广泰生化制品有限公司 枸橼酸他莫昔芬颗粒
MX390899B (es) 2015-10-30 2025-03-21 Cancer Prevention Pharmaceuticals Inc Formulación de combinación de dosis fija, eflornitina y sulindaco.
CN113133982B (zh) * 2021-03-30 2022-08-02 北京鑫开元医药科技有限公司 一种阿那曲唑片及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4543370A (en) * 1979-11-29 1985-09-24 Colorcon, Inc. Dry edible film coating composition, method and coating form
US4683256A (en) * 1980-11-06 1987-07-28 Colorcon, Inc. Dry edible film coating composition, method and coating form
GB8501035D0 (en) * 1985-01-16 1985-02-20 Senior J Prostaglandins
US4832956A (en) * 1985-09-25 1989-05-23 Gerhard Gergely Disintegrating tablet and process for its preparation
US5681382A (en) * 1995-08-22 1997-10-28 Shin-Etsu Chemical Co., Ltd. Rapidly soluble coating composition and method for preparing same
US6245352B1 (en) * 1999-04-27 2001-06-12 Eli Lilly And Company Pharmaceutical formulation

Also Published As

Publication number Publication date
WO2003035043A3 (en) 2003-06-05
GB0125492D0 (en) 2001-12-12
EP1448171A2 (en) 2004-08-25
JP2005508971A (ja) 2005-04-07
WO2003035043A2 (en) 2003-05-01
US20050042279A1 (en) 2005-02-24

Similar Documents

Publication Publication Date Title
AU2002313236A1 (en) Medicinal compositions
GB0102342D0 (en) Pharmaceutical formulation
AU2002363361A1 (en) Pharmaceutical compositions containing oxybutynin
GB0118689D0 (en) Pharmaceutical formulation
AU2002257582A1 (en) Pharmaceutical formulation
AU2002302147A1 (en) Pharmaceutical composition
PL366432A1 (en) Pharmaceutical formulation
AU2002258221A1 (en) Medicinal composition
IL161306A0 (en) Pharmaceutical formulation comprising (r)-bicalutamide
AU2002341145A1 (en) Pharmaceutical formulation comprising more than 15% tamoxifen
AU2002246659A1 (en) Benzoylalkylindolepyridinium compounds and pharmaceutical compositions comprising such compounds
AU2002354460A1 (en) Medicinal composition
AU2002246658A1 (en) Benzoylalkylindolepyridinium compounds and pharmaceutical compositions comprising such compounds
AUPR529701A0 (en) Pharmaceutical composition
AU2002346223A1 (en) Medicinal compositions
GB0104749D0 (en) Pharmaceutical formulation
HK1066478A (en) Pharmaceutical formulation comprising (r)-bicalutamide
AU2001230490A1 (en) Pharmaceutical formulation
HK1064031A (en) Pharmaceutical formulation
HK1062263A (en) Pharmaceutical formulation
HK1066162A (en) Pharmaceutical formulation
HK1066729A (en) Pharmaceutical formulation comprising bicalutamide
HK1059743A (en) Pharmaceutical formulation comprising bicalutamide
AU2001286181A1 (en) Pharmaceutical composition comprising (-)-secoisolariciresinol
AU2002339723A1 (en) Pharmaceutical composition comprising chito-oligomers

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase